EA201892687A1 - Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение - Google Patents

Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение

Info

Publication number
EA201892687A1
EA201892687A1 EA201892687A EA201892687A EA201892687A1 EA 201892687 A1 EA201892687 A1 EA 201892687A1 EA 201892687 A EA201892687 A EA 201892687A EA 201892687 A EA201892687 A EA 201892687A EA 201892687 A1 EA201892687 A1 EA 201892687A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
proteinkinase
activity
application
crystal form
Prior art date
Application number
EA201892687A
Other languages
English (en)
Russian (ru)
Inventor
Цунсинь Лян
Юнбинь Ма
Вэй ХЭ
Original Assignee
ЭксКАВЕРИ ХОЛДИНГЗ, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭксКАВЕРИ ХОЛДИНГЗ, ИНК. filed Critical ЭксКАВЕРИ ХОЛДИНГЗ, ИНК.
Publication of EA201892687A1 publication Critical patent/EA201892687A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
EA201892687A 2016-06-01 2017-06-01 Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение EA201892687A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/084300 2016-06-01
PCT/CN2017/086760 WO2017206924A1 (zh) 2016-06-01 2017-06-01 抑制蛋白激酶活性化合物的晶型及其应用

Publications (1)

Publication Number Publication Date
EA201892687A1 true EA201892687A1 (ru) 2019-06-28

Family

ID=60477983

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892687A EA201892687A1 (ru) 2016-06-01 2017-06-01 Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение

Country Status (17)

Country Link
US (1) US10899744B2 (cg-RX-API-DMAC7.html)
EP (1) EP3470410B1 (cg-RX-API-DMAC7.html)
JP (1) JP7054528B2 (cg-RX-API-DMAC7.html)
KR (1) KR102466958B1 (cg-RX-API-DMAC7.html)
CN (1) CN109195964B (cg-RX-API-DMAC7.html)
AU (1) AU2017274110B2 (cg-RX-API-DMAC7.html)
CA (1) CA3026142C (cg-RX-API-DMAC7.html)
EA (1) EA201892687A1 (cg-RX-API-DMAC7.html)
ES (1) ES2981015T3 (cg-RX-API-DMAC7.html)
IL (1) IL263356B (cg-RX-API-DMAC7.html)
MY (1) MY188379A (cg-RX-API-DMAC7.html)
PH (1) PH12018502529A1 (cg-RX-API-DMAC7.html)
PL (1) PL3470410T3 (cg-RX-API-DMAC7.html)
RU (1) RU2744264C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201810800VA (cg-RX-API-DMAC7.html)
TW (1) TWI646094B (cg-RX-API-DMAC7.html)
WO (1) WO2017206924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279579B2 (en) 2018-06-21 2023-02-01 Betta Pharmaceuticals Co Ltd Crystalline form of a compound to inhibit the activity of cdk4/6 and its use
WO2022031636A1 (en) 2020-08-03 2022-02-10 Teva Pharmaceuticals International Gmbh Solid state forms of ensartinib and ensartinib salts
CN117897156A (zh) * 2021-08-10 2024-04-16 贝达药业股份有限公司 恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
KR102851417B1 (ko) * 2022-08-16 2025-08-28 제이투에이치바이오텍 (주) 피리미딘-4-카복사마이드 화합물의 결정형 및 이를 포함하는 경구용 약학 제제
CN118021811A (zh) * 2023-12-28 2024-05-14 复旦大学附属华山医院 一种靶向于csf1r激酶的6-氟吡啶甲酰苯胺类抑制剂、药物组合物及其核素成像试剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2002002643A0 (en) * 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
US8414489B2 (en) 2003-11-13 2013-04-09 Medtronic Minimed, Inc. Fabrication of multi-sensor arrays
CA2577937C (en) * 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP1786777A1 (en) 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
PT1963302E (pt) 2005-12-05 2013-04-09 Pfizer Prod Inc Polimorfos de um inibidor de c-met/hgfr
CN101652068A (zh) * 2007-01-19 2010-02-17 艾科睿制药公司 激酶抑制物化合物
KR101691640B1 (ko) * 2008-06-19 2016-12-30 엑스커버리 홀딩 컴퍼니 엘엘씨 키나아제 억제제 화합물로서의 치환된 피리다진 카르복사마이드 화합물
EA025030B1 (ru) * 2010-10-08 2016-11-30 Икскавери Холдинг Кампани, Ллс Соединение {5-[(1r)-1-(2,6-дихлор-3-фторфенил)этокси]-6-аминопиридазин-3-ил}-n-(1-метил-6-оксо-1,6-дигидропиридин-3-ил)карбоксамид в качестве киназного ингибитора
EP2625176B1 (en) * 2010-10-08 2016-08-17 Xcovery Holding Company LLC Substitututed 6-amino-pyridazin-3-yl-carboxamide compounds as protein kinase modulators

Also Published As

Publication number Publication date
KR20190012231A (ko) 2019-02-08
WO2017206924A1 (zh) 2017-12-07
US20190135792A1 (en) 2019-05-09
HK1259249A1 (zh) 2019-11-29
TWI646094B (zh) 2019-01-01
SG11201810800VA (en) 2019-01-30
RU2744264C2 (ru) 2021-03-04
AU2017274110A1 (en) 2019-01-24
US10899744B2 (en) 2021-01-26
PL3470410T3 (pl) 2024-09-16
JP2019518026A (ja) 2019-06-27
ES2981015T3 (es) 2024-10-04
AU2017274110B2 (en) 2021-05-06
NZ788961A (en) 2024-12-20
NZ750921A (en) 2024-12-20
IL263356B (en) 2022-08-01
CA3026142A1 (en) 2017-12-07
RU2018145183A3 (cg-RX-API-DMAC7.html) 2020-07-16
EP3470410A4 (en) 2019-12-04
TW201742865A (zh) 2017-12-16
CN109195964B (zh) 2021-08-10
EP3470410B1 (en) 2024-04-17
RU2018145183A (ru) 2020-07-14
PH12018502529A1 (en) 2019-04-08
EP3470410A1 (en) 2019-04-17
CN109195964A (zh) 2019-01-11
IL263356A (en) 2018-12-31
CA3026142C (en) 2024-02-13
BR112018074612A2 (pt) 2019-03-19
JP7054528B2 (ja) 2022-04-14
MY188379A (en) 2021-12-07
KR102466958B1 (ko) 2022-11-14

Similar Documents

Publication Publication Date Title
PH12019501707A1 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
MX2015018032A (es) Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.
JOP20200042A1 (ar) مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها
PH12018502529A1 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
MX2019002212A (es) Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos.
SA520411843B1 (ar) Trpc6 مشتقات بيريدين كربونيل والاستخدام الطبي لها كمثبطات
TN2018000130A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
BR112018075206A2 (pt) tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
NZ721645A (en) Compounds for use as gpr120 agonists
JOP20210329A1 (ar) مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
MX389330B (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
MX379558B (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3-il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino)-benzamida.
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
TN2016000491A1 (en) Carboxamide derivatives.
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
MX387639B (es) Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base.
MX2022000154A (es) Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos.
JP2016537396A5 (cg-RX-API-DMAC7.html)
NZ750921B2 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof